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A case of multiple inflamed skin lesions
and cellulitis in a 68-year-old male
patient with relapsed chronic lymphocytic
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Abstract
Introduction: Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used for a variety of B cell hematological
malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed in up to 32% of the
patients on ibrutinib. The mechanism in which ibrutinib can cause skin toxicities has been thought due to the inhibition of
epidermal growth factor; c-Kit and platelet-derived growth factor receptor). Here, we report a case of an elderly chronic
lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating
ibrutinib therapy.
Case report: A 68-year-old male patient with relapsed chronic lymphocytic leukemia was started on ibrutinib 420mg
orally daily following multiple lines of therapy. Three months following ibrutinib, the patient developed multiple hyper
pigmented lesions over both forearms then over both thighs; buttocks and lower limbs. The lesions were labeled as
ecthyma and cellulitis that started as papules, which progressed to pustules.
Management and outcomes: The patient required admission in which he received prolonged course of antibiotics.
Biopsy from the wound showed soft tissue fragment infiltrated by acute and chronic inflammatory cells with necrosis;
rare foreign body giant cells and granulation tissue formation; suggestive of abscess. Subsequently, ibrutinib was stopped
permanently.
Discussion: This is the first case description of an ibrutinib-associated sever skin toxicity in Qatar. The provided
information regarding the clinical descriptions of toxicity profiles in general and skin-based in particular is valuable
information for daily clinical practice, especially when selecting the optimum first-line treatment for the patient.
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Introduction
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK)
inhibitor. It is approved by the United States (US)
Food and Drug Administration (FDA) for a variety of
B cell hematological malignancies including chronic
lymphocytic leukemia (CLL); mantle cell lymphoma
(MCL) and Waldenstrom macroglobulinemia (WM).1,2
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Cutaneous adverse effects of ibrutinib include rash (12%
to 29%); petechiae; pruritus (11% to 14%) and skin
infections (14% to 16%).1–3 Several cases have reported
variable skin toxicities to ibrutinib therapy in CLL; MCL
and WM patients.4–10 Here, we report an elderly CLL
patient who developed multiple inflamed skin lesions
and cellulitis after 100 days from initiating ibrutinib.
Case presentation
A 68-year-old white male patient, who is a known case
of hypertension; chronic artery disease; dyslipidemia;
hypothyroidism and prostate cancer was diagnosed
with CLL Stage III in 2008. The patient’s home medica-
tions included: levothyroxine 100mcg daily; rosuvastatin
10mg daily; amlodipine 5mg daily and vitamin D2
50,000 IU weekly. The patient was kept under watch
and wait approach as his complete blood count (CBC)
parameters were under acceptable range. In 2012, his
white blood count (WBC) started to increase; platelet
count started to drop and his bone marrow exam was
consistent with disease progression. The patient received
a total of six cycles of chemotherapy Bendamustine and
Rituximab (BR) in 2013, which was complicated by
intractable diarrhea and reactivation of hepatitis B.
The patient was followed by gastroenterology team
and was kept on tenofovir disoproxil 245mg daily.
The patient completed his treatment course and was in
remission until February 2015 when he started com-
plaining from cervical lymphadenopathy. Images were
requested accordingly, including computerized tomog-
raphy (CT) of thorax and abdomen on February 2015,
which showed newly developed multiple mediastinal;
axillary; retroperitoneal and mesenteric lymph node.
In June 2015, the patient started complaining from B
symptoms manifested by weight loss; anorexia; on and
off fever along with Coombs positive anemia that failed
to respond to steroids and increased in transfusion
demands. Repeated CT was performed which showed
stationary course of the disease and bone marrow find-
ings were consistent with persistent bone marrow
involvement by B-cell CLL (11 q deletion) with
increased prolymphocytes. Thus, the patient was
started on ibrutinib 420mg orally daily.
Ibrutinib treatment course
In July 2015, the patient developed clostridium difficile
infection; which was treated and he was stable until
October 2015 when he stated to have multiple skin
lesions labeled as ecthyma and cellulitis that started
as papules, which progressed to pustules. In addition,
hyperpigmented lesions started to progress over both
forearms then over both thighs; buttocks and lower
limbs. The patient was followed by dermatology upon
which he was prescribed local antibiotic cream (fusidic
acid 2% twice daily) and lotions. However, the skin
lesions were persistent over his left lower limb for
about one month without any improvement.
The patient was admitted on March 2016 for further
investigations. Consequently, wound incision and drain-
age was performed along with regular follow-up with
wound care. Biopsy from the wound showed soft tissue
fragment infiltrated by acute and chronic inflammatory
cells with necrosis; rare foreign body giant cells and
granulation tissue formation; suggestive of abscess.
Culture from the tissue showed Staphylococcus aureus
sensitive strain and the patient was started on ciprofloxa-
cin 500mg orally every 12h and clindamycin 450mg
orally every 6h. Work up for tuberculosis was negative
as well as Epstein bar virus and cytomegalovirus.
Ibrutinib treatment was stopped and it was decided not
to resume ibrutinib treatment again (Figure 1).
Causality assessment
Several assessment scales are available to assess adverse
drug reaction causality. The Naranjo scale is a valid
evaluation tool, which uses 10 assessment points to
Figure 1. Multiple inflamed skin lesions, marked as cellulitis on
both arms and legs.
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evaluate the probability of a drug-induced cause.11 The
scale consists of 10 questions and the total score range
from 4 to +13; the reaction is considered definite if
the score is 9 or higher, probable if 5 to 8, possible if 1
to 4 and doubtful if 0 or less. The total score obtained
was 10 in our patient’s case.
Discussion
With respect to ibrutinib’s side effect profile, it is worth
mentioning that it is associated with a 25% incidence
of cutaneous rashes according to Pharmacyclics
Pharmaceuticals FDA-approved patient
information.1–3 Cutaneous adverse effects of ibrutinib
include rash (12% to 29%); petechiae; pruritus (11% to
14%) and skin infections (14% to 16%).1–3 Several
cases have reported variable skin toxicities to ibrutinib
therapy in CLL; MCL and WM patients.4,12,13 A thor-
ough database search to review the literature for any
evidence regarding ibrutinib-associated dermatological
adverse events was performed. In early phase clinical
trials, ibrutinib was tested as monotherapy in MCL,
CLL and small lymphocytic leukemia (SLL), and it
was associated with a frequency of 13–27% of rash
occurrence.2–6 An open-label, multicenter, phase 1 b/2
trial published in the lancet oncology in 2014 included
31 patients at least 65 years old previously untreated
with symptomatic CLL or SLL requiring therapy.
Patients received 28 days cycles of once daily ibrutinib
420mg or ibrutinib 840mg. The primary endpoint was
safety of the dose-fixed regimen with respect to fre-
quency and severity of adverse events. Adverse events
reported from first dose up to 30 days of last dose of
ibrutinib were petechiae (16%) and 13% in each of the
following: cellulitis; erythema and rash pruritus.
In addition to being a BTK inhibitor and despite
having high selectivity for BTK, it exerts off-target
effects on other kinases, such as epidermal growth
factor receptor (EGFR). Ibrutinib was shown to effect-
ively inhibit EGFR in a dose-dependent manner.
Inhibition of EGFR is known to enhance apoptosis
and inhibit cell cycle progression, which stimulates
apoptosis and inflammation. As cutaneous eruptions
are considered common side effects to EGFR inhibition
by other tyrosine kinase inhibitors, ibrutinib-induced
rash may be attributed to inhibition of EGFR.8
Another proposed mechanism of ibrutinib-induced
drug eruption is through inhibition of c-Kit and plate-
let-derived growth factor receptor (PDGFR), similar to
imatinib which is a tyrosine kinase inhibitor used in the
treatment of chronic myeloid leukemia (CML).10
A case report published in the American journal of
hematology in 2015 presented a 67-year-old man with
17 p deletion CLL who was started on ibrutinib 420mg
PO daily. Two weeks after therapy initiation, the
patient developed a painless, non-pruritic rash in the
form of a diffuse distribution of bright red edematous
papules, 0.5–1 cm in diameter that began on his wrists
and then spread to his entire body. The rash also
involved his palms and soles and had a peripheral-to-
central pattern of spread. His absolute eosinophil count
was within the normal range (100/mm3). Ibrutinib was
suspended and after several days his rash had com-
pletely resolved. Since the patient was on allopurinol
which can cause the rash, allopurinol was stopped
and the patient was restarted on a lower ibrutinib
dose 140mg oral once daily. After a single dose, he
developed recurrence of his full-body rash then
Naranjo adverse drug reactions probability Scale.
Question Yes No
Don’t
know Score
1. Are there previous conclu-
sive reports on this
reaction?
+1 0 0 +1
2. Did the adverse event appear
after the suspected drug
was administered?
+2 1 0 +2
3. Did the adverse reaction
improve when the drug
was discontinued, or a
specific antagonist was
administered?
+1 0 0 +1
4. Did the adverse reaction
reappear when the drug
was readministered?
+2 1 0 +2
5. Are there alternative causes
(other than the drug) that
could on their own have
caused the reaction?
1 +2 0 +2
6. Did the reaction reappear
when a placebo was given?
1 +1 0 0
7. Was the drug detected in the
blood (or other fluids) in
concentrations known to
be toxic?
+1 0 0 0
8. Was the reaction more
severe when the dose was
increased, or less severe
when the dose was
decreased?
+1 0 0 0
9. Did the patient have a similar
reaction to the same or
similar drug in any previ-
ous exposure?
+1 0 0 +1
10. Was the adverse event con-
firmed by any objective
evidence?
+1 0 0 +1
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ibrutinib was again stopped. The rash again dis-
appeared within several days of stopping ibrutinib. As
the clinical features distinguishing the rash from an
allopurinol-mediated rash is edematous papules in con-
trast to the morbilliform rash associated with allopur-
inol, the associated toxicity was attributed to ibrutinib.
A single center experience published in the British
journal of hematology included 14 patients (13 CLL,
1 MCL) who developed rash while receiving ibrutinib
at the Stanford Cancer Center. There were two distinct
rash subtypes observed: (i) a no palpable, largely
asymptomatic petechial rash and (ii) a palpable erup-
tion characterized by pruritic, non-blanching, viol-
aceous papules clinically resembling leucocytoclastic
vasculitis. The study concluded that the early onset
(15 days after drug initiation) palpable purpuric rash
varied in severity and resulted in temporary stop of the
medication, while the late onset (80 days after drug
initiation) non-palpable rash was mild and required
no dose adjustment of ibrutinib.7
Another case report published in the American jour-
nal of dermatopathology in 2016 presented a 70-year-
old white male patient with stage CLL who was being
treated with ibrutinib and rituximab. He developed a
distinguishable eruption in the form of bilateral, pur-
puric, painful cutaneous nodules which resolved when
the drug was discontinued. The reason why the authors
believe that ibrutinib is the causative factor is the
appearance of the nodules during the fourth month of
therapy which increased in size, sensitivity and number
until the drug was stopped at six months. At that point,
they regressed and disappeared completely within six
weeks.1 In addition, a case report published in skin
diseases and skin care in 2017 regarding a 59-year-old
Caucasian male with a history of CLL who was being
treated for two years with ibrutinib 420mg once daily.
The patient was tolerating it quite well and reported no
adverse effects until one day he presented with a five
days old pruritic maculopapular rash with multiple
hemorrhagic bullae involving skin, palms which was
first diagnosed as varicella zoster and he was given
oral acyclovir but the rash was getting worse. It first
appeared on the palms as reddish raised lesions then
black colored blisters started to appear followed by
lesions on the trunk of the body, lower extremities as
well as around his mouth. It was associated with swel-
ling of the lips and bilateral hands. Ibrutinib was
stopped and the patient was given IV steroids and anti-
histamines. The rash started to resolve and became
less itchy and the bullae decreased in size in the next
three days.9
Moreover, the first case report for ibrutinib-induced
Sweet syndrome was published in the American journal
of dermatopathology regarding a 64-year-old woman
with 12 p deletion CLL who was treated with ibrutinib
and developed several erythematous, painful, palpable
red to violaceous papulo-nodular skin lesions in the
limbs; neck and face one year after therapy initiation.
She was diagnosed with neutrophilic dermatosis based
on skin biopsy. Ibrutinib was stopped and topical ster-
oids were given after which a rapid resolution of the
rash occurred. Ibrutinib was restarted at a lower dose
(280mg once daily) three months later and there was no
recurrence of her cutaneous lesions. However, when the
dose increased to 420mg once daily, recurrence of the
Sweet syndrome occurred which led to treatment cessa-
tion after which they completely disappeared.14 Here,
ibrutinib skin adverse events were shown to be dose-
dependent and this effect has been observed in Sweet
syndrome associated with imatinib, another tyrosine
kinase inhibitor.15
Ibrutinib-associated skin toxicity was also reported
in patients with WM. A case report published in derma-
tology reports in 2017 described a case of a 79-year-old
male patient with WM receiving ibrutinib who after 12
weeks of initiating ibrutinib developed a painless red
maculopapular non-pruritic rash which started from
the groins and wrists then spread to extremities, trunk
and face. The rash resolved with two weeks of topical
steroids and with no modification (tapering, suspending
or discontinuation) of ibrutinib regimen. This was the
first case report to present ibrutinib-associated rash in a
WM patient and the patient had similar presentation to
the one reported in the American journal of hematol-
ogy in 2015 but later onset (12 weeks vs. 2 weeks).8
So far three subtypes of ibrutinib-related skin
inflammation have been reported in the literature: (1)
leukocytoclastic vasculitis like pruritic violaceous
palpable purpura, (2) painless non-pruritic edematous
papules with centripetal spread and (3) asymptomatic
non-palpable petechial rash.2,7 Whether the association
with skin toxicity occurrence is dose depended is still
unknown. The management of skin toxicities was either
complete cessation of the drug, suspending then restart-
ing at a lower dosage or continuation of therapy while
observing.
Conclusion
Here, we report an elderly CLL patient who developed
multiple skin lesions and cellulitis in 100 days after
initiating ibrutinib therapy. This is the first case descrip-
tion of an ibrutinib-associated severe skin toxicity in
Qatar. The provided information regarding the clinical
descriptions of toxicity profiles in general and skin-
based in particular is valuable information for daily
clinical practice, especially when selecting the optimum
first-line treatment for the patient. Our case report con-
tributes in generating a shared clinical experience that
can be useful for recognition and management of
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ibrutinib-associated skin toxicity. The importance of
our valuable data is as high as the increasing demand
of ibrutinib use in CLL as well as other approved indi-
cations, such as MCL and chronic GVHD
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